Avicanna Inc. (FRA:0NN)

Market Cap	11.08M -45.5%
Revenue (ttm)	15.60M -0.2%
Net Income	-2.30M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0765
Previous Close	0.0765
Day's Range	0.0765 - 0.0765
52-Week Range	0.0645 - 0.1930
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatol...

• Industry: Pharmaceutical Preparations
• Founded: 2016
• Employees: 112
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0NN

Financial Performance

In 2025, Avicanna's revenue was 25.48 million, an increase of 0.08% compared to the previous year's 25.46 million. Losses were -2.76 million, -39.75% less than in 2024.

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error